Chinese Firms Expand Solo Global Phase III Activity Including US Sites

Indicative Of Independent Growth

 
• By Dexter Jie Yan
  
from 2024 to 2025
2024's seven global Phase III trials opened solely by Chinese firms was the second least since 2020. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Scrip Perspectives